Devyser

DVYSR.ST

Stockholm, Sweden· Est. 2004

devyser.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Total funding raised: $17M

Market Cap: $175.2MFounded: 2004Employees: ~100HQ: Stockholm, Sweden

Sector Ranking#56 in Diagnostics & Precision Medicine

Overview

Devyser's mission is to make personalized healthcare universally accessible by providing diagnostic labs with simplified, robust, and integrated genetic testing solutions. Since its founding in 2004, the company has established a strong portfolio of CE-IVD and RUO NGS kits, achieving a global footprint in over 45 countries. Its strategy focuses on deepening its presence in core verticals like transplantation and oncology through product innovation, strategic acquisitions (e.g., Cybergene), and partnerships (e.g., Illumina supply agreement), while navigating the regulatory pathway for key market entries, including the US.

Post-Transplantation MonitoringOncologyReproductive HealthHereditary Diseases (Cystic Fibrosis, Thalassemia, Cardiovascular)

Technology Platform

Integrated platform of targeted, multiplexed PCR-based NGS test kits coupled with proprietary bioinformatics software for analysis, interpretation, and reporting, creating streamlined end-to-end workflows for clinical labs.

Funding History

Total raised:$17M

Series B$12MUndisclosedOct 15, 2020

Series A$5MUndisclosedMay 15, 2018

Opportunities

Significant growth is driven by the global trend of internalizing complex genetic testing in hospital labs, the expansion of clinical NGS applications, and specific catalysts like the Illumina supply agreement and pending FDA submissions.

The markets for transplantation monitoring (especially liquid biopsy) and comprehensive hereditary disease testing are large and underpenetrated.

Risk Factors

Key risks include regulatory delays in achieving FDA approval for critical products, intense competition from larger diagnostics firms and service labs, and execution risks associated with technological integration post-acquisition.

The company's growth is also tied to the continued adoption rate of its targeted NGS kit model over alternative testing approaches.

Competitive Landscape

Devyser competes with large diversified diagnostics firms (Roche, Thermo Fisher), specialized NGS kit providers (ArcherDX/Invitae, Qiagen), and large service labs (Quest, Labcorp). Its differentiation lies in its deep vertical focus, integrated kit-software solutions, and reputation for user-friendly, efficient workflows designed specifically for clinical laboratories.